{"id":17283,"date":"2014-03-14T08:36:20","date_gmt":"2014-03-14T12:36:20","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=17283"},"modified":"2014-03-14T08:26:12","modified_gmt":"2014-03-14T12:26:12","slug":"chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283","title":{"rendered":"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 03\/14\/2014 (wallstreetpr) &#8211; <b>Chimerix Inc. (NASDAQ:CMRX)\u2019s <\/b>stock has been rising in the market by as much as 18.2% after the company received an approval from the FDA, for the use of one of its pill to try and save the life a 7 year old boy who is suffering from a viral infection.<\/p>\n<p style=\"text-align: justify;\">Chimerix Inc. (NASDAQ:CMRX)<b> <\/b>will enroll the boy as its first patient in a 20 patient pilot trial for its open label brincidofir (CMX001) drug. The drug is essentially used to treat adenovirus infections in patients with failing immune systems. The drug has officially been approved by the FDA and will be used as the last means of action in the attempt of saving the dying baby.<\/p>\n<p style=\"text-align: justify;\">The approval comes at the back of increased attention and lobbying from the general public, a move that has essentially forced FDA to stem into actions its compassionate user policy that allows drug makers to administer un-approved treatments to patients in life threatening conditions.<\/p>\n<p style=\"text-align: justify;\"><b>Chimerix Fourth quarter and full year results<\/b><\/p>\n<p style=\"text-align: justify;\">Chimerix Inc. (NASDAQ:CMRX)<b> <\/b>last updated its financial results for the fourth quarter and full year on March 7, 2014 in which the company reported a net loss of $8.2 million for the fourth quarter. This was almost double the net loss of $4.3 million reported in 2012 same quarter.<\/p>\n<p style=\"text-align: justify;\">Revenue for the fourth quarter came in at $879,000 a massive drop compared to a high of $3.6 million for the same period the prior year. Research and development expenses on the other hand came in at $6.3 million. Loss from operations for the quarter came in at $8 million with the pharmaceutical company reporting a balance sheet of $110 million as of close of business on December 31, 2013.<\/p>\n<p style=\"text-align: justify;\">Full year net loss came in at $36.4 million compared to a net loss of $4.4 million in 2012, revenues for the year dropped to $4.4 million down from a high of $33.7 million reported in 2012.<\/p>\n<p style=\"text-align: justify;\">Chimerix Inc. (NASDAQ:CMRX)<b> <\/b>was up in Thursday trading session closing the day at a high of $26.40 after moving up by a high of 7.40%<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 03\/14\/2014 (wallstreetpr) &#8211; Chimerix Inc. (NASDAQ:CMRX)\u2019s stock has been rising in the market by as much as 18.2% after the company received an [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":17294,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[5180,5181],"stock_ticker":[],"class_list":["post-17283","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-chimerix-inc-nasdaqcmrx","tag-nasdaqcmrx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 03\/14\/2014 (wallstreetpr) &#8211; Chimerix Inc. (NASDAQ:CMRX)\u2019s stock has been rising in the market by as much as 18.2% after the company received an [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-14T12:36:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"645\" \/>\n\t<meta property=\"og:image:height\" content=\"363\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby\",\"datePublished\":\"2014-03-14T12:36:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg\",\"keywords\":[\"Chimerix Inc. (NASDAQ:CMRX)\",\"NASDAQ:CMRX\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283\",\"name\":\"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg\",\"datePublished\":\"2014-03-14T12:36:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg\",\"width\":645,\"height\":363},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283","og_locale":"en_US","og_type":"article","og_title":"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby - Wall Street PR","og_description":"Boston, MA 03\/14\/2014 (wallstreetpr) &#8211; Chimerix Inc. (NASDAQ:CMRX)\u2019s stock has been rising in the market by as much as 18.2% after the company received an [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-03-14T12:36:20+00:00","og_image":[{"width":645,"height":363,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby","datePublished":"2014-03-14T12:36:20+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg","keywords":["Chimerix Inc. (NASDAQ:CMRX)","NASDAQ:CMRX"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283","url":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283","name":"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg","datePublished":"2014-03-14T12:36:20+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Chimerix-Inc.-logo.jpg","width":645,"height":363},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/chimerix-inc-nasdaqcmrx-surging-after-fda-approval-of-its-pill-to-save-a-dying-baby-17283#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Chimerix Inc. (NASDAQ:CMRX) Surging After FDA Approval Of Its Pill, To Save A Dying Baby"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/17283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=17283"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/17283\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/17294"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=17283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=17283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=17283"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=17283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}